Mouse EP3 α, β, and γ Receptor Variants Reduce Tumor Cell Proliferation and Tumorigenesis in VivoInes Macias‐Perez, Ambra Pozzi|Journal of Biological Chemistry|2008Cited by 28
Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) PatientsIan W. Flinn, John D. Hainsworth, Ines Macias‐Perez et al.|Blood|2010Cited by 8
A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety AnalysisJesús G. Berdeja, Ian W. Flinn, Daniel R. Couriel et al.|Blood|2011Cited by 2